PCT/US00/12536

5

15

20

25

35

What is claimed is:

- 1. A method of inducing the formation of kidney epithelia which comprises contacting mesenchymal precursors, in the presence of a growth factor, with an amount of a purified gpl30 receptor ligand effective to induce the formation of kidney epithelia.
- 2. The method of claim 1, wherein the gp130 receptor ligand is a leukemia inhibitory factor.
 - 3. A method of inducing the differentiation of fetal tissue, fetal cells, or fetal or postnatal precursor or stem cells into kidney nephrons in a subject with diminished kidney function, which comprises administering to the subject, in the presence of a growth factor, an amount of a gp130 receptor ligand effective to induce differentiation of such fetal tissue, fetal cells, or fetal or postnatal precursor or stem cells into kidney nephrons.
 - 4. The method of claim 3, wherein the fetal tissue, fetal cells, or fetal or postnatal precursor or stem cells are treated with a gp130 receptor ligand ex vivo, in the presence of a growth factor, and the so treated fetal tissue, fetal cells, or fetal or postnatal precursor or stem cells are then transplanted into the subject with diminished kidney function.
- 30 5. The method of claim 3, wherein the gpl30 receptor ligand is a leukemia inhibitory factor.
 - 6. A method of treating a subject suffering from kidney failure which comprises administering to the subject, in the presence of a growth factor, an amount of a gp130 receptor ligand effective to treat the subject's kidney failure.
 - 7. The method of claim 6, wherein the gp130 receptor

WO 00/66147 PCT/US00/12536

36

ligand is a leukemia inhibitory factor.

5

10

30

35

- 8. A method of preserving a kidney for transplantation which comprises contacting the kidney, in the presence of a growth factor, with an amount of a gpl30 receptor ligand effective to preserve the kidney.
- 9. The method of claim 8, wherein the gp130 receptor ligand is a leukemia inhibitory factor.
- 10. The method of claim 1, 4, or 8, wherein the effective amount of the gpl30 receptor ligand is an amount from about 5 ng/ml to about 200 ng/ml.
- 15 11. The method of claim 3 or 6, wherein the effective amount of the gp130 receptor ligand is an amount from about 1 μ g/kg to about 50 μ g/kg of body weight.
- 12. The method of claim 1, 3, 6, or 8, wherein the gp130 receptor ligand is a cardiotrophin, an oncostatin M, a ciliary neuronotrophic factor, or an interleukin-6.
- 13. The method of claim 1, 3, 6, or 8, wherein the growth factor is one or more of a TGFα, a FGF-2, a FGF-9, a TIMP-1, or a TIMP-2.
 - 14. The method of claim 1, 4, or 8, wherein the growth factor is TGFα, FGF-2, or FGF-9 and the effective amount of TGFα, FGF-2, or FGF-9 is an amount from about 1 ng/ml to about 100 ng/ml.
 - 15. The method of claim 3 or 6, wherein the growth factor is TGF α , FGF-2, or FGF-9 and the effective amount of TGF α , FGF-2, or FGF-9 is an amount from about 0.1 μ g/kg to about 25 μ g/kg of body weight.
 - 16. The method of claim 1, 4, or 8, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of

WO 00/66147 PCT/US00/12536

TIMP-1 or TIMP-2 is an amount from about 200 ng/ml to about 2 μ g/ml.

- 17. The method of claim 3 or 6, wherein the growth factor is TIMP-1 or TIMP-2 and the effective amount of TIMP-1 or TIMP-2 is an amount from about 25 μ g/kg to about 500 μ g/kg of body weight.
- 18. The method of any of claims 1, 3, 6, or 8, wherein the gp130 receptor ligand is a polypeptide comprising a sequence identical to a naturally occurring human gp130 receptor ligand.

5

- 19. The method of any of claims 2, 5, 7, or 9, wherein the leukemia inhibitory factor is a polypeptide comprising a sequence identical to a naturally occurring human leukemia inhibitory factor.
- 20. The method of any of claims 1, 3, 6, or 8, wherein the growth factor is a polypeptide comprising a sequence identical to a naturally occurring human growth factor.
- 21. A method of inducing the formation of kidney epithelia which consists essentially of contacting mesenchymal precursors, in the presence of a growth factor, with an amount of a gp130 receptor ligand effective to induce the formation of kidney epithelia.